Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy

HIV Medicine

Volumn 18, Issue 4, 2017, Pages 284-291

  Milazzo, L ^a   Lai, A ^a   Calvi, E ^a   Ronzi, P ^a   Micheli, V ^a   Binda, F ^a   Ridolfo, A L ^a   Gervasoni, C ^a   Galli, M ^a   Antinori, S ^a   Sollima, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

direct acting antivirals; hepatitis C virus kinetics; hepatitis C virus polymorphisms; hepatitis C virus HIV coinfection

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DACLATASVIR; DARUNAVIR; DASABUVIR; DOLUTEGRAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LEDIPASVIR; MARAVIROC; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR;

ADULT; AGED; ANEMIA; ANTIRETROVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REBOUND; TREATMENT FAILURE; TREATMENT RESPONSE; COINFECTION; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ADMINISTRATION, ORAL; AGED; ANTIVIRAL AGENTS; COINFECTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84989227469     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12429     Document Type: Article

References (29)

1. Weber R, Sabin CA, Friis-Møller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 1632–1641.
2. Smith C, Sabin CA, Lundgren JD et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D Study. AIDS 2010; 24: 1537–1548.
3. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800–1805.
4. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992–1002.
5. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIVinfected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49:1605–1615.
6. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (509–516): e501.
7. Limketkai BN, Mehta SH, Sutcliffe CG et al. Relationship of liver disease stage and antiviral therapy with liver related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370–378.
8. Kovari H, Ledergerber B, Cavassini M et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. J Hepatol 2015; 63: 573–580.
9. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27–F36.
10. Rodriguez-Torres M, Slim J, Bhatti L et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012; 13: 142–152.
11. Mehta SH, Lucas GM, Mirel LB et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361–2369.
12. Cotte L, Braun J, Lascoux-Combe C et al. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59: 1768–1776.
13. Sulkowski M, Pol S, Mallolas J et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597–605.
14. Romero-Gomez M, Berenguer M, Molina E, Calleja JL. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 2013; 59: 1323–1330.
15. Burger D, Back D, Buggisch P et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013; 58: 792–800.
16. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179–185.
17. Sulkowski MS, Naggie S, Lalezari J et al. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. JAMA 2014; 312: 353–361.
18. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705–713.
19. Sulkowski MS, Eron JJ, Wyles D et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223–1231.
20. Wyles DL, Ruane PJ, Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714–725.
21. Nascimento Cavalcante L, Castro Lyra A. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015;7:1617–1631.
22. European association for study of liver. EASL Recommendations on Treatment of Hepatitis C. J Hepatol 2015; 63: 199–236.
23. Verbist BM, Thys K, Reumers J et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering. Bioinformatics 2015; 31: 94–101.
24. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat 2015; 22: 861–870.
25. Sulkowski MS, Vargas HE, Di Bisceglie AM et al. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology 2016; 150: 419–429.
26. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–954.
27. Wang G, Sherrill-Mix S, Chang K, Quince C, Bushman FD. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 2010; 84: 6218–6228.
28. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64: 486–504.
29. Khatri A, Dutta S, Wang H et al. Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infect Dis 2016; 62: 972–979.